Guest guest Posted November 9, 2005 Report Share Posted November 9, 2005 Hello Ladies, Great News,On November4,2006, a U.S House-Senate conferance committee dropped a controversial provision that gave the Drug Enforcement Administration (DEA) authority to review, and potentially block, the sale of all new prescription opioids.The legislation,promoted by Rep. R. Wolf and attached to a multi- department appropriations bill,passed last year with little notice. This year, however, the food and drug administration(FDA) pharmaceutical manufacturers,doctors who treat people with pain and many others objected to renewing it,and the provision was stripped from the bill.Opponents of bill believed that the provision was an unwarranted intrusion by a law enforcement agency into the FDA's grug-review system. Pain specialists also said that DEA reviews could jeoparize development of new drugs needed by people with chronic pain.The Congressional Appropriations Conference Committee decided to remove language from the proposed appropriate bill that would have allowed the DEA to force delays or veto newly approved FDA pain medicines from reaching the market. The troublesome ammendment was removed from the final bill.The American Pain Foundation along with the American Academy of Pain Medicine and others worked to inform the public and the Conferees about the potential harm to people with pain if this amendment were enacted. Kind Regards,Tami Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.